Form 4: Quest Diagnostics Executive Sam Samad Acquires Additional Shares Through Dividend Reinvestment
SEC Form 4 Filing
Executive Vice President & CFO of Quest Diagnostics, Sam Samad, reports acquiring 35 shares of common stock through a dividend reinvestment plan.
Summary
- On January 29, 2025, Sam Samad, Executive Vice President & CFO of Quest Diagnostics, acquired 35 shares of common stock.
- The shares were acquired through a dividend reinvestment plan at a price of $158.036 per share.
- Following the transaction, Samad directly owns 17,539 shares of Quest Diagnostics common stock.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The transaction reflects a routine activity (dividend reinvestment) and aligns executive interests with shareholders.
Positives
- The acquisition of shares through a dividend reinvestment plan demonstrates Samad's continued investment in Quest Diagnostics.
Industry Context
Executive stock ownership is often viewed as a positive sign, aligning management's interests with those of shareholders. Dividend reinvestment plans are a common way for executives to increase their holdings over time.
Stakeholder Impact
- The transaction signals confidence from a key executive, which could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 01/29/2025 | Date of transaction: Sam Samad acquired 35 shares of common stock. |
| 01/31/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.